Second Sight Medical Products (EYES) Shares are Down -0.24%

Second Sight Medical Products (EYES) has risen sharply, recording gains of 16.01% in the past 4 weeks. However, the stock has corrected -0.24% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.67% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

Second Sight Medical Products (NASDAQ:EYES): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.40 and $4.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.47. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.13, notching a gain of 1.47% for the day. The total traded volume was 997,119 . The stock had closed at $4.07 on the previous day.


The stock has recorded a 20-day Moving Average of 8.38% and the 50-Day Moving Average is 7.23%. Second Sight Medical Products, Inc. has dropped 23.66% during the last 3-month period . Year-to-Date the stock performance stands at -29.88%.

Second Sight Medical Products, Inc. is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Companys product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant, a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU), and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada, Turkey, and at one medical center in Saudi Arabia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *